New triple therapy could improve diabetes control
NCT ID NCT03899402
First seen May 30, 2026 · Last updated Jun 16, 2026 · Updated 3 times
Summary
This study tests whether adding two extra medications (semaglutide and dapagliflozin) to insulin helps adults with type 1 diabetes control their blood sugar better than insulin alone or with just one extra drug. The 78 participants, aged 18-70 with a BMI of 25 or higher, will be followed for 12 months. The main goal is to see if the triple therapy lowers HbA1c, a key measure of long-term blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Diabetes and Endocrinology Research Center of WNY
Williamsville, New York, 14221, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.